Exploring the Mechanisms of Venetoclax Resistance Via Drug Screening and Genome-Wide CRISPR Screening

威尼斯人 抗药性 医学 药理学 癌症研究 肿瘤科 白血病 计算生物学 生物 免疫学 慢性淋巴细胞白血病 遗传学
作者
Adriana Ladungová,Helena Peschelová,Lenka Dostalova,Y. Lodhi,Narendra Varma Gottumukkala,Jiřı́ Mayer,Michal Šmída
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 5759-5759
标识
DOI:10.1182/blood-2023-189245
摘要

Introduction: Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study. Methods: First, we generated a model of the venetoclax resistance from 3 AML cell lines: MOLM-13, HL-60 and MV4-11. Resistance was achieved through chronic administration of the compound, inhibiting cell viability to 80-90% in multiple rounds by gradually increasing concentrations until the cells developed resistance. We have then characterized these Venetoclax-resistant (VeR) cells using quantitative RT-PCR and RNA sequencing to reveal the mechanisms behind their resistance. VeR cell lines were subjected to drug screening with a library of 859 FDA and EMA-approved compounds with various clinical indications. Cell viability in response to the drug library was assessed after 72h by Cell-Titer Glo and evaluated against the wild-type counterparts. Top-performing compounds were validated in dose-response curves, and synergy scores were identified from combinational treatments. Simultaneously, we performed genome-wide CRISPR/Cas9 knockout screening using Brunello CRISPR knockout library on both MOLM-13 wild-type (WT) and VeR cell lines to identify genes that maintain the resistance to venetoclax and genes that may potentially synergize with targeting BCL-2. Results: Results from the CRISPR screen pointed out multiple genes whose loss of function may contribute to venetoclax resistance in MOLM-13 cells, among which BAX, NOXA, ELAVL1 and TP53 ranked as top hits. On the contrary, we also identified several genes whose loss of function sensitized the cells to venetoclax (e.g., MCL1, OPA1, CDK2, MCAT), suggesting them to be promising therapeutic targets. Among these hits, CDK2 correlates with our drug screening data indicating Flavopiridol as an effective compound in treating VeR cell lines. Moreover, we confirmed the elevated MCL1 gene expression for the MOLM-13 VeR cell line through RNAseq (and qPCR) and detected an altered expression of genes mainly in metabolic pathways and PI3K-Akt signaling pathway via differential gene expression analysis. Our drug screening results revealed overall high efficacy of DNA-damaging agents, proteasome and HDAC inhibitors for both WT and VeR cell lines. We also included an MCL1 inhibitor as a positive control in our drug library and confirmed a synergistic effect when combined with venetoclax. Conclusion: Integrating a range of screening approaches may lead to discovering previously unknown therapeutic targets for venetoclax-resistant AML. Our screens confirmed previously described involvement of the apoptotic pathway genes in venetoclax resistance as well as identified some novel promising targets. Our ongoing efforts involve thorough validations of the identified hits from CRISPR and drug screening to enhance the reliability and translatability of the results. This project was partly supported by grants MUNI/A/1330/2021, MUNI/A/1419/2021 OPRDE (No.CZ.02.2.69/0.0/0.0/19_073/0016943) and project NICR (EU program EXCELES, No. LX22NPO5102).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
EZ完成签到 ,获得积分10
2秒前
831143完成签到 ,获得积分0
2秒前
3秒前
3秒前
快乐的90后fjk完成签到 ,获得积分10
4秒前
4秒前
orixero应助欣欣采纳,获得10
5秒前
大大杰完成签到,获得积分10
5秒前
Tal完成签到,获得积分10
5秒前
dzy1317发布了新的文献求助10
6秒前
6秒前
大大杰发布了新的文献求助10
8秒前
善良又亦完成签到 ,获得积分10
8秒前
zh发布了新的文献求助10
8秒前
Neonoes完成签到,获得积分10
10秒前
Eason小川发布了新的文献求助10
13秒前
kiyo_v完成签到,获得积分10
16秒前
lengyan发布了新的文献求助10
17秒前
俊逸的香萱完成签到,获得积分10
20秒前
zhang完成签到 ,获得积分10
22秒前
黄花完成签到 ,获得积分10
23秒前
zdnn完成签到,获得积分10
25秒前
小梦完成签到,获得积分10
25秒前
lieeey完成签到,获得积分10
27秒前
不敢装睡完成签到,获得积分10
31秒前
lengyan完成签到,获得积分10
31秒前
yangzhang完成签到,获得积分10
31秒前
Euuii完成签到 ,获得积分10
32秒前
May应助dominate采纳,获得10
32秒前
方圆完成签到 ,获得积分10
33秒前
Xu发布了新的文献求助10
33秒前
35秒前
甜菜完成签到,获得积分10
35秒前
佳佳应助大大杰采纳,获得10
38秒前
吕绪特发布了新的文献求助10
38秒前
40秒前
标致幻然完成签到 ,获得积分10
41秒前
饱满的新之完成签到 ,获得积分10
41秒前
bai完成签到,获得积分10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3965786
求助须知:如何正确求助?哪些是违规求助? 3511071
关于积分的说明 11156136
捐赠科研通 3245633
什么是DOI,文献DOI怎么找? 1793097
邀请新用户注册赠送积分活动 874230
科研通“疑难数据库(出版商)”最低求助积分说明 804268